A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response
Clinical Infectious Diseases · 14.06.2024 · 78 (6) · 1462-1472
DOI: 10.1093/cid/ciad792 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical Infectious Diseases, online erschienen am 02.02.2024. Verfasst von Pablo C Okhuysen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Infection Control, and Employee Heatlh, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Vancomycin, Clostridium Infections, Anti-Bacterial Agents, Clostridioides difficile. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, Summit, Inc.
Abstract (Originalsprache)
Background
Exposure to antibiotics predisposes to dysbiosis and Clostridioides difficile infection (CDI) that can be severe, recurrent (rCDI), and life-threatening. Nonselective drugs that treat CDI and perpetuate dysbiosis are associated with rCDI, in part due to loss of microbiome-derived secondary bile acid (SBA) production. Ridinilazole is a highly selective drug designed to treat CDI and prevent rCDI.
Methods
In this phase 3 superiority trial, adults with CDI, confirmed with a stool toxin test, were randomized to receive 10 days of ridinilazole (200 mg twice daily) or vancomycin (125 mg 4 times daily). The primary endpoint was sustained clinical response (SCR), defined as clinical response and no rCDI through 30 days after end of treatment. Secondary endpoints included rCDI and change in relative abundance of SBAs.
Results
Ridinilazole and vancomycin achieved an SCR rate of 73% versus 70.7%, respectively, a treatment difference of 2.2% (95% CI: −4.2%, 8.6%). Ridinilazole resulted in a 53% reduction in recurrence compared with vancomycin (8.1% vs 17.3%; 95% CI: −14.1%, −4.5%; P = .0002). Subgroup analyses revealed consistent ridinilazole benefit for reduction in rCDI across subgroups. Ridinilazole preserved microbiota diversity, increased SBAs, and did not increase the resistome. Conversely, vancomycin worsened CDI-associated dysbiosis, decreased SBAs, increased Proteobacteria abundance (∼3.5-fold), and increased the resistome.
Conclusions
Although ridinilazole did not meet superiority in SCR, ridinilazole greatly reduced rCDI and preserved microbiome diversity and SBAs compared with vancomycin. These findings suggest that treatment of CDI with ridinilazole results in an earlier recovery of gut microbiome health. Clinical Trials Registration.Ri-CoDIFy 1 and 2: NCT03595553 and NCT03595566.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Infection Control, and Employee Heatlh, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Henry Ford Health, Detroit, Michigan, USA.
- Foothills Medical Center and University of Calgary, Calgary, Canada.
- Aversi Clinic, Tbilisi, Georgia.
- Reina Sofia University Hospital-IMIBIC, University of Córdoba, CIBERINFEC, Cordoba, Spain.
- Santa Casa de Belo Horizonte, Belo Horizonte, Brazil.
ORCID-Profile: Julian Torre-Cisneros, Jose G Montoya, Mark Wilcox
Förderung
- Administration for Strategic Preparedness and Response
- Biomedical Advanced Research and Development Authority
- Summit, Inc
Zitieren
APA
Okhuysen, P. C., Ramesh, M. S., Louie, T., Kiknadze, N., Torre-Cisneros, J., de Oliveira, C. M., Van Steenkiste, C., Stychneuskaya, A., Garey, K. W., Garcia-Diaz, J., Li, J., Duperchy, E., Chang, B. Y., Sukbuntherng, J., Montoya, J. G., Styles, L., Clow, F., James, D., Dubberke, E. R., & Wilcox, M. (2024). A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response. Clinical Infectious Diseases, 78(6), 1462-1472. https://doi.org/10.1093/cid/ciad792
Vancouver
Okhuysen PC, Ramesh MS, Louie T, Kiknadze N, Torre-Cisneros J, de Oliveira CM, et al. A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response. Clinical Infectious Diseases. 2024;78(6):1462-1472. doi:10.1093/cid/ciad792
BibTeX
@article{Okhuysen2024,
author = {Okhuysen, Pablo C and Ramesh, Mayur S and Louie, Thomas and Kiknadze, Nino and Torre-Cisneros, Julian and de Oliveira, Claudia Murta and Van Steenkiste, Christophe and Stychneuskaya, Alena and Garey, Kevin W and Garcia-Diaz, Julia and Li, Jianling and Duperchy, Esther and Chang, Betty Y and Sukbuntherng, Juthamas and Montoya, Jose G and Styles, Lori and Clow, Fong and James, Danelle and Dubberke, Erik R and Wilcox, Mark},
title = {A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response},
journal = {Clinical Infectious Diseases},
year = {2024},
volume = {78},
number = {6},
pages = {1462--1472},
doi = {10.1093/cid/ciad792}
}
EUVIMED